Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Swedish Orphan Biovitrum AB ( (SE:SOBI) ) is now available.
Sobi has entered into a capped royalty purchase agreement with Apellis Pharmaceuticals, significantly reducing its ex-U.S. royalty obligations for Aspaveli in exchange for a $275 million upfront payment and potential milestone payments. This strategic move underscores Sobi’s commitment to advancing treatments for rare diseases, particularly C3G and IC-MPGN, and highlights the potential of Aspaveli to transform patient outcomes in these areas.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company focused on developing and delivering innovative treatments for rare diseases. With approximately 1,900 employees worldwide, Sobi operates across Europe, North America, the Middle East, Asia, and Australia, generating a revenue of SEK 26 billion in 2024. The company is listed on Nasdaq Stockholm.
Average Trading Volume: 354,659
Current Market Cap: SEK97.75B
For detailed information about SOBI stock, go to TipRanks’ Stock Analysis page.